NDUFS1-Mediated Mitochondrial Complex I Activity Maintains Pancreatic Cancer Stemness by Promoting PAX2 Hypomethylation

Abstract

Pancreatic cancer is highly refractory and aggressive, with cancer stem cells (CSCs) being primarily responsible for its metastasis and chemoresistance. Deregulated cellular bioenergetics is a hallmark of cancer cells. However, the influence of bioenergetics on the maintenance of pancreatic CSC stemness and its underlying mechanisms have not been fully elucidated. In this study, pancreatic CSCs, isolated either by sorting ALDH⁺ subpopulation or enriching serially passaged tumorspheres from pancreatic cancer cells and PDX model, exhibited active mitochondrial complex I activity and increased oxidative phosphorylation. Complex I maintains stemness and tumorigenicity through its core subunit, NDUFS1. NDUFS1-mediated pancreatic CSC stemness is reinforced by high expression of CD147, which promotes pSTAT3^Tyr705-mediated NDUFS1 transcription. To promote stemness, CD147-NDUFS1 initiates SIRT1-DNMT1 metaboloepigenetic signaling, decreasing promoter hypomethylation and increasing the mRNA expression of the stem cell transcript factor PAX2. Moreover, NDUFS1 and CD147 expressions were highly correlated in pancreatic cancer tissues, and their co-expression was significantly associated with poor patient survival. Taken together, our study provides evidence that mitochondrial complex I functions as a key player in CSC stemness maintenance through NDUFS1-mediated retrograde metaboloepigenetic signaling. Blocking a key regulator of mitonuclear communication by targeting CD147 may be a novel therapy for pancreatic cancer.

Keywords

CD147 / complex I / NDUFS1 / pancreatic cancer stem cells / PAX2

References

[1] R. L. Siegel, T. B. Kratzer, A. N. Giaquinto, H. Sung, and A. Jemal, “Cancer Statistics, 2025,” CA: A Cancer Journal for Clinicians 75, no. 1 (2025): 10–45.

[2] A. Mannucci and A. Goel, “Advances in Pancreatic Cancer Early Diagnosis, Prevention, and Treatment: The Past, the Present, and the Future,” CA: A Cancer Journal for Clinicians 76, no. 1 (2025): e70035.

[3] Y. Pan, C. Yuan, C. Zeng, et al., “Cancer Stem Cells and Niches: Challenges in Immunotherapy Resistance,” Molecular Cancer 24, no. 1 (2025): 52.

[4] I. Stouras, M. Vasileiou, P. F. Kanatas, E. Tziona, C. Tsianava, and S. Theocharis, “Metabolic Profiles of Cancer Stem Cells and Normal Stem Cells and Their Therapeutic Significance,” Cells 12, no. 23 (2023): 2686.

[5] M. Tufail, C. H. Jiang, and N. Li, “Altered Metabolism in Cancer: Insights Into Energy Pathways and Therapeutic Targets,” Molecular Cancer 23, no. 1 (2024): 203.

[6] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31–46.

[7] H. Jiang and J. Ye, “The Warburg Effect: The Hacked Mitochondrial-Nuclear Communication in Cancer,” Seminars in Cancer Biology 112 (2025): 93–111.

[8] A. Viale, P. Pettazzoni, C. A. Lyssiotis, et al., “Oncogene Ablation-Resistant Pancreatic Cancer Cells Depend on Mitochondrial Function,” Nature 514, no. 7524 (2014): 628–632.

[9] P. Sancho, E. Burgos-Ramos, A. Tavera, et al., “MYC/PGC-1alpha Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells,” Cell Metabolism 22, no. 4 (2015): 590–605.

[10] Z. Rong, J. Xu, J. Yang, et al., “CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression,” Cancer Research 84, no. 24 (2024): 4246–4263.

[11] R. K. Nimmakayala, F. Leon, S. Rachagani, et al., “Metabolic Programming of Distinct Cancer Stem Cells Promotes Metastasis of Pancreatic Ductal Adenocarcinoma,” Oncogene 40, no. 1 (2021): 215–231.

[12] J. J. Loh and S. Ma, “Hallmarks of Cancer Stemness,” Cell Stem Cell 31, no. 5 (2024): 617–639.

[13] H. Lee, B. Kim, J. Park, et al., “Cancer Stem Cells: Landscape, Challenges and Emerging Therapeutic Innovations,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 248.

[14] H. Du, T. Xu, S. Yu, S. Wu, and J. Zhang, “Mitochondrial Metabolism and Cancer Therapeutic Innovation,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 245.

[15] C. Uslu, E. Kapan, and A. Lyakhovich, “Cancer Resistance and Metastasis Are Maintained Through Oxidative Phosphorylation,” Cancer Letters 587 (2024): 216705.

[16] T. Zhao, L. He, L. P. Wong, et al., “Derepressing Nuclear Pyruvate Dehydrogenase Induces Therapeutic Cancer Cell Reprogramming,” Cell Metabolism 37, no. 8 (2025): 1667–1681.

[17] F. Bonnay, A. Veloso, V. Steinmann, et al., “Oxidative Metabolism Drives Immortalization of Neural Stem Cells During Tumorigenesis,” Cell 182, no. 6 (2020): 1490–1507.

[18] W. Hu, X. Cui, H. Liu, et al., “CYP3A5 Promotes Glioblastoma Stemness and Chemoresistance Through Fine-Tuning NAD(+)/NADH Ratio,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 3.

[19] A. Chaves-Perez, S. E. Millman, S. Janaki-Raman, et al., “Metabolic Adaptations Direct Cell Fate During Tissue Regeneration,” Nature 643, no. 8071 (2025): 468–477.

[20] K. Ma, H. Cheng, L. Wang, et al., “Succinate Preserves CD8(+) T Cell Fitness to Augment Antitumor Immunity,” Immunity 58, no. 10 (2025): 2505–2523.

[21] E. Cuyas, S. Verdura, N. Folguera-Blasco, et al., “Mitostemness,” Cell Cycle 17, no. 8 (2018): 918–926.

[22] L. Peruzzotti-Jametti, C. M. Willis, G. Krzak, et al., “Mitochondrial Complex I Activity in Microglia Sustains Neuroinflammation,” Nature 628, no. 8006 (2024): 195–203.

[23] D. Bezwada, L. Perelli, N. P. Lesner, et al., “Mitochondrial Complex I Promotes Kidney Cancer Metastasis,” Nature 633, no. 8031 (2024): 923–931.

[24] T. M. Malta, A. Sokolov, A. J. Gentles, et al., “Machine Learning Identifies Stemness Features Associated With Oncogenic Dedifferentiation,” Cell 173, no. 2 (2018): 338–354.

[25] J. Fan, R. Tian, X. Yang, et al., “KCNN4 Promotes the Stemness Potentials of Liver Cancer Stem Cells by Enhancing Glucose Metabolism,” International Journal of Molecular Sciences 23, no. 13 (2022): 6958.

[26] X. Y. Fan, D. He, C. B. Sheng, et al., “Therapeutic Anti-CD147 Antibody Sensitizes Cells to Chemoradiotherapy via Targeting Pancreatic Cancer Stem Cells,” American Journal of Translational Research 11, no. 6 (2019): 3543–3554.

[27] L. Li, W. Tang, X. Wu, et al., “HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s,” Clinical Cancer Research 19, no. 24 (2013): 6703–6715.

[28] X. Wu, W. Tang, R. T. Marquez, et al., “Overcoming Chemo/Radio-Resistance of Pancreatic Cancer by Inhibiting STAT3 Signaling,” Oncotarget 7, no. 10 (2016): 11708–11723.

[29] V. M. Wang, R. M. M. Ferreira, J. Almagro, et al., “CD9 Identifies Pancreatic Cancer Stem Cells and Modulates Glutamine Metabolism to Fuel Tumour Growth,” Nature Cell Biology 21, no. 11 (2019): 1425–1435.

[30] J. Brandi, I. Dando, E. D. Pozza, et al., “Proteomic Analysis of Pancreatic Cancer Stem Cells: Functional Role of Fatty Acid Synthesis and Mevalonate Pathways,” Journal of Proteomics 150 (2017): 310–322.

[31] I. Vercellino and L. A. Sazanov, “The Assembly, Regulation and Function of the Mitochondrial respiratory Chain,” Nature Reviews Molecular Cell Biology 23, no. 2 (2022): 141–161.

[32] F. A. Urra, F. Munoz, A. Lovy, and C. Cardenas, “The Mitochondrial Complex(I)ty of Cancer,” Frontiers in Oncology 7 (2017): 118.

[33] Y. A. Shen, C. C. Chen, B. J. Chen, et al., “Potential Therapies Targeting Metabolic Pathways in Cancer Stem Cells,” Cells 10, no. 7 (2021): 1772.

[34] A. P. M. Beerkens, S. Heskamp, F. V. Reinema, G. J. Adema, P. N. Span, and J. Bussink, “Mitochondria Targeting of Oxidative Phosphorylation Inhibitors to Alleviate Hypoxia and Enhance Anticancer Treatment Efficacy,” Clinical Cancer Research 31, no. 7 (2025): 1186–1193.

[35] S. Alcala, L. Villarino, L. Ruiz-Canas, et al., “Targeting Cancer Stem Cell OXPHOS With Tailored Ruthenium Complexes as a New Anti-Cancer Strategy,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 33.

[36] M. Picard and O. S. Shirihai, “Mitochondrial Signal Transduction,” Cell Metabolism 34, no. 11 (2022): 1620–1653.

[37] R. Zou, J. Tao, J. Qiu, et al., “Ndufs1 Deficiency Aggravates the Mitochondrial Membrane Potential Dysfunction in Pressure Overload-Induced Myocardial Hypertrophy,” Oxidative Medicine and Cellular Longevity 2021 (2021): 5545261.

[38] B. Qi, L. He, Y. Zhao, et al., “Akap1 Deficiency Exacerbates Diabetic Cardiomyopathy in Mice by NDUFS1-Mediated Mitochondrial Dysfunction and Apoptosis,” Diabetologia 63, no. 5 (2020): 1072–1087.

[39] F. Ren, D. B. Wang, T. Li, Y. H. Chen, and Y. Li, “Identification of Differentially Methylated Genes in the Malignant Transformation of Ovarian Endometriosis,” Journal of Ovarian Research 7 (2014): 73.

[40] J. Ellinger, M. Poss, M. Bruggemann, et al., “Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma,” Clin Genitourin Cancer 15, no. 4 (2017): e551–e562.

[41] C. Y. Su, Y. C. Chang, C. J. Yang, M. S. Huang, and M. Hsiao, “The Opposite Prognostic Effect of NDUFS1 and NDUFS8 in Lung Cancer Reflects the Oncojanus Role of Mitochondrial Complex I,” Scientific Reports 6 (2016): 31357.

[42] D. Wu, L. He, Z. Xu, et al., “The Combination of NDUFS1 With CD4(+) T Cell Infiltration Predicts Favorable Prognosis in Kidney Renal Clear Cell Carcinoma,” Frontiers in Cell and Developmental Biology 11 (2023): 1168462.

[43] J. Zhan, S. Sun, Y. Chen, et al., “MiR-3130-5p Is an Intermediate Modulator of 2q33 and Influences the Invasiveness of Lung Adenocarcinoma by Targeting NDUFS1,” Cancer Medicine 10, no. 11 (2021): 3700–3714.

[44] T. Chen, D. Li, Y. Wang, et al., “Loss of NDUFS1 Promotes Gastric Cancer Progression by Activating the Mitochondrial ROS-HIF1alpha-FBLN5 Signaling Pathway,” British Journal of Cancer 129, no. 8 (2023): 1261–1273.

[45] S. H. Kim and S. V. Singh, “The FoxQ1 Transcription Factor Is a Novel Regulator of Electron Transport Chain Complex I Subunits in Human Breast Cancer Cells,” Molecular Carcinogenesis 61, no. 3 (2022): 372–381.

[46] L. Dong, L. Luo, Z. Wang, et al., “Targeted Degradation of NDUFS1 by Agrimol B Promotes Mitochondrial ROS Accumulation and Cytotoxic Autophagy Arrest in Hepatocellular Carcinoma,” Free Radical Biology and Medicine 220 (2024): 111–124.

[47] L. Ren, L. Meng, J. Gao, et al., “PHB2 Promotes Colorectal Cancer Cell Proliferation and Tumorigenesis Through NDUFS1-Mediated Oxidative Phosphorylation,” Cell Death & Disease 14, no. 1 (2023): 44.

[48] A. Sharanek, A. Burban, M. Laaper, et al., “OSMR Controls Glioma Stem Cell Respiration and Confers Resistance of Glioblastoma to Ionizing Radiation,” Nature Communications 11, no. 1 (2020): 4116.

[49] K. K. Wong, “DNMT1 as a Therapeutic Target in Pancreatic Cancer: Mechanisms and Clinical Implications,” Cellular Oncology 43, no. 5 (2020): 779–792.

[50] B. Q. Xu, Z. G. Fu, Y. Meng, et al., “Gemcitabine Enhances Cell Invasion via Activating HAb18G/CD147-EGFR-pSTAT3 Signaling,” Oncotarget 7, no. 38 (2016): 62177–62193.

[51] Q. Huang, J. Li, J. Xing, et al., “CD147 Promotes Reprogramming of Glucose Metabolism and Cell Proliferation in HCC Cells by Inhibiting the p53-Dependent Signaling Pathway,” Journal of Hepatology 61, no. 4 (2014): 859–866.

[52] X. Li, Y. Zhang, W. Ma, et al., “Enhanced Glucose Metabolism Mediated by CD147 Contributes to Immunosuppression in Hepatocellular Carcinoma,” Cancer Immunology, Immunotherapy 69, no. 4 (2020): 535–548.

[53] K. Wang, W. Huang, R. Chen, et al., “Di-Methylation of CD147-K234 Promotes the Progression of NSCLC by Enhancing Lactate Export,” Cell Metabolism 33, no. 1 (2021): 160–173.

[54] J. Li, Q. Huang, X. Long, et al., “CD147 Reprograms Fatty Acid Metabolism in Hepatocellular Carcinoma Cells Through Akt/mTOR/SREBP1c and P38/PPARalpha Pathways,” Journal of Hepatology 63, no. 6 (2015): 1378–1389.

[55] J. Xu, Z. Y. Shen, X. G. Chen, et al., “A Randomized Controlled Trial of Licartin for Preventing Hepatoma Recurrence After Liver Transplantation,” Hepatology 45, no. 2 (2007): 269–276.

[56] H. Bian, J. S. Zheng, G. Nan, et al., “Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation,” JNCI: Journal of the National Cancer Institute 106, no. 9 (2014): dju239.

[57] F. Feng, B. Wang, X. Sun, et al., “Metuzumab Enhanced Chemosensitivity and Apoptosis in Non-Small Cell Lung Carcinoma,” Cancer Biology & Therapy 18, no. 1 (2017): 51–62.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.